Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Common Equity (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Common Equity for 4 consecutive years, with $7.3 million as the latest value for Q4 2025.

  • Quarterly Common Equity rose 179.69% to $7.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Dec 2025, up 179.69% year-over-year, with the annual reading at $7.3 million for FY2025, 179.69% up from the prior year.
  • Common Equity for Q4 2025 was $7.3 million at bioAffinity Technologies, down from $8.9 million in the prior quarter.
  • The five-year high for Common Equity was $12.6 million in Q3 2022, with the low at -$16.8 million in Q2 2022.
  • Average Common Equity over 4 years is $3.1 million, with a median of $5.1 million recorded in 2023.
  • Peak annual rise in Common Equity hit 185.23% in 2025, while the deepest fall reached 162.22% in 2025.
  • Over 4 years, Common Equity stood at $11.0 million in 2022, then plummeted by 56.03% to $4.9 million in 2023, then plummeted by 46.41% to $2.6 million in 2024, then surged by 179.69% to $7.3 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $7.3 million, $8.9 million, and -$2.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.